Medytox is seeking a rebound in earnings amid litigation risks. The company is focusing on accelerating its push into global markets, including by hiring a clinical expert from a global pharmaceutical company this year.
The company's flagship product is a botulinum toxin formulation used to temporarily relax muscles to improve skin wrinkles. Medytox established its market position by launching the botulinum toxin drug "Meditoxin" in 2006, the first in Korea and the fourth in the world. Founder and CEO Chung Hyun-ho graduated from the microbiology department at Seoul National University and is an executive-turned-researcher who studied cell and molecular biology at the Korea Advanced Institute of Science and Technology (KAIST).
But years of legal disputes have also hampered the company's growth. In 2020, the Ministery of Food and Drug Safety revoked Meditoxin's product approval, prompting the company to file an administrative suit that concluded with the Supreme Court's final ruling in favor of the company in Mar. 2025. Separately, long-running strain and manufacturing process disputes with Daewoong Pharmaceutical and Hugel have added to management burdens.
◇ Settlement ends China partner dispute... earnings at the "early recovery" stage
With Medytox resolving its key lawsuits, observers say the burden has eased. The dispute with its China partner also ended in a settlement, averting the possibility of a large payout. The company had seen legal expenses surge due to various lawsuits, at times resulting in operating losses.
On a consolidation basis, last year's revenue came to 247.3 billion won, up 8% from a year earlier, marking a record high for the third straight year. However, operating profit and net profit fell to 17.2 billion won and 15.5 billion won, respectively, from the prior year. Increases in selling and administrative expenses, business restructuring, and legal costs collectively played a role.
By business, the toxin segment grew 25% year over year, driven by domestic growth of "Coretox" and expanded overseas entry of "NEWLUX." In contrast, the filler segment fell 5% from a year earlier, showing a divergence between businesses.
Legal expenses fell from 11.9 billion won in the first quarter to 6.3 billion won in the third quarter last year, but then jumped to 19.0 billion won in the fourth quarter. This led to a swing to loss in the fourth quarter. With expenses fluctuating, profitability is also seen as unstable. While the top line is growing, analysts say it is still hard to view the fundamentals as solid.
Compared with other listed companies, the company's governance structure is relatively simple. On the 2nd, Medytox disclosed that CEO and largest shareholder Chung Hyun-ho used a stock-collateral loan to purchase an additional 7,342 shares. With this purchase, Chung's equity stake rose to 18.23%.
The combined equity stakes of Chung's two sons amount to just 0.02%. To succeed to management control, they would need large-scale equity gifts or purchases, and gift tax would also apply, which could become a burden depending on cash capacity.
◇ Global gap persists… staking everything on overseas expansion
Industry watchers say Medytox has reached a proving ground where it must demonstrate structural improvement. More corporations are entering the aesthetic medical market, and the pace of changes in technology and treatment trends is quickening, intensifying competition.
Medytox's biggest structural limitation is the lack of presence in core global markets. It has yet to enter the United States and China on a commercial basis, even though they are the centers of the botulinum toxin and filler markets.
The company secured annual production capacity of about 600 billion won by expanding its Osong Plant 3, but utilization is constrained due to gaps in key markets. With intensifying competition in the domestic market, the need to expand overseas is growing even greater.
Medytox is also strengthening its global business strategy. A prime example is the recent hiring of Executive Director Lee Tae-sang to head R&D. With more than 20 years of clinical development experience at global pharmaceutical companies and a track record of leading U.S. and European approvals, the move is seen as a step to reinforce overseas expansion.
The company is also diversifying its business portfolio. Medytox launched "NewBijou," an injection for submental fat reduction approved as Korea's 40th domestically developed new drug, as it pushes to expand in medical aesthetics. It is also preparing to launch "LactiPlan," a probiotic for body fat reduction. As the new businesses are in early stages, observers say mid- to long-term growth trends need to be watched.
A Medytox official said, "We are carrying out projects to enter advanced countries with next-generation toxin formulations," adding, "We are actively pursuing approval procedures to formally register Numeco's new toxin formulation 'NEWLUX' in about 20 overseas countries."
The official said, "We expect the new products scheduled for launch this year to have a positive impact on mid- to long-term earnings growth," adding, "We will build competitiveness in the global aesthetics market."